Radioactive treatment for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced clear cell kidney cancer that has gotten worse after at least one prior treatment (including an immunotherapy and a targeted therapy).
- Your cancer must show up as 'PSMA-positive' on a special PET/CT scan, with no spots that are 'PSMA-negative'.
- At least one tumor must be measurable on a CT or MRI scan, and you must be able to do your daily activities without much help (ECOG 0-1).
- Your blood test results must be within a certain range (for example, kidney function and liver function must be good enough).
- You must be 18 or older and willing to use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a radioactive medicine (called 161Tb-PSMA) that delivers radiation directly to kidney cancer cells that have a specific marker (PSMA). It is for people whose kidney cancer has spread and has not responded to at least two prior treatments. The goal is to see if this new therapy can help shrink the cancer.
This study tests a radioactive drug called Lu-177 PSMA to see if it can help people with advanced kidney cancer that has not responded to other treatments. It aims to slow the cancer's growth and improve quality of life.
This trial tests a radioactive treatment called 177Lu-PSMA-617 for advanced liver cancer that has not responded to first-line immunotherapy. You need a PSMA-PET scan first to see if your cancer absorbs the treatment.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
This study tests a new type of radiation therapy that targets kidney cancer cells. It is for people whose cancer has returned or spread after at least two prior treatments, and aims to see if it can shrink tumors and slow the disease.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Hear when a new Metastatic Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.